期刊
AMERICAN JOURNAL OF PATHOLOGY
卷 186, 期 6, 页码 1649-1661出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.ajpath.2016.01.015
关键词
-
类别
资金
- NIH [CA91645, HL65301, HL083151, 5P30GM103392, ROIDK078161]
- Department of Defense grant from the Ovarian Cancer Research Program [W81XWH-13-OCRP-PA]
- American Heart Association [GRNT20460045]
- Chemotherapy Foundation
- Bioinformatics Core grant [P20 RR181789]
- Maine Medical Center
Evidence suggests that stromal cells play critical roles in tumor growth. Uncovering new mechanisms that control stromal cell behavior and their accumulation within tumors may lead to development of more effective treatments. We provide evidence that the HU177 cryptic collagen epitope is selectively generated within human ovarian carcinomas and this collagen epitope plays a role in SKOV-3 ovarian tumor growth in vivo. The ability of the HU177 epitope to regulate SKOV-3 tumor growth depends in part on its ability to modulate stromal cell behavior because targeting this epitope inhibited angiogenesis and, surprisingly, the accumulation of alpha-smooth muscle actin-expressing stromal cells. Integrin beta 10 beta 1 can serve as a receptor for the HU177 epitope in alpha-smooth muscle actin-expressing stromal cells and subsequently regulates Erk-dependent migration. These findings are consistent with a mechanism by which the generation of the HU177 collagen epitope provides a previously unrecognized alpha(10)beta(1) ligand that selectively governs angiogenesis and the accumulation of stromal cells, which in turn secrete protumorigenic factors that contribute to ovarian tumor growth. Our findings provide a new mechanistic understanding into the roles by which the HU177 epitope regulates ovarian tumor growth and provide new insight into the clinical results from a phase 1 human clinical study of the monoclonal antibody D93/TRC093 in patients with advanced malignant tumors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据